In this fifth part of our series in collaboration with Analysis Group, Wayne chats with Dr. Hilary Marston, Principal at Canal Row Advisors; Dr. Donna Rivera, Executive Vice President of Clinical Evidence Modernization at Canal Row Advisors; and Dr. Mei Sheng Duh, Managing Principal and Chief Epidemiologist at Analysis Group. Together, they discuss the growing role of RWE in oncology drug approvals, methodological and statistical considerations for external control arms and RWE-based study designs, addressing bias and confounding in oncology research, improving clinical trial diversity and transportability, evaluating the contribution of components in combination therapies, the impact of breakthrough therapies and evolving standards of care on oncology drug development, the ARPA-H SURPASS initiative and its implications for oncology trials, the role of advanced analytics in modernizing oncology research, and much more. This episode and the rest of our series do not include the usual He
In this fourth part of our series in collaboration with Analysis Group, Wayne chats with Dr. Marianne Cunnington, Managing Principal at Analysis Group, and Dr. Robert Reynolds, Vice President and Head of Development Sciences at GSK. Together, they discuss the evolution of postmarketing drug surveillance, the current scope of postmarketing studies, triggers for postmarketing commitments and requirements, safety and effectiveness questions best addressed after approval, studying populations excluded from clinical trials, standards for robust postmarketing evidence, real-world evidence in confirmatory studies, AI and automation in postmarketing research, transparency in study protocols and results, FDA monitoring and enforcement of postmarketing requirements, and much more. This episode and the rest of our series do not include the usual Headlines segment. To subscribe or find out more information about our podcast, visit FDAWatch.net (http://www.fdawatch.net/). Want to be a sponsor, mark